Leading proteomics player gets a trio of new partners; GV tries to prevent cervical cancer
A little over 6 months ago, John Baker got on a call from a CEO with a strange request.
Baker is head of innovation at Abcam, a British company that provides life science research tools to labs and companies around the world. A lot of the firm’s work involves supplying highly specific antibodies that allow scientists to detect the presence of or fish out a specific protein in a sample.
Sujal Patel, CEO of Nautilus Biotechnology, wanted basically the opposite. “Their first call to us was, ‘Hey, guys, we’re looking for some really bad antibodies,’” Baker recalled. “‘What have you got beyond trenching in a freezer for things that had failed?’”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.